title: Honokiol: a novel natural agent for cancer prevention and therapy.
abstract: Honokiol (3',5-di-(2-propenyl)-1,1'-biphenyl-2,4'-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
authors: Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA.
authors: S
authors: S
authors: Arora
authors: S
authors: S
authors: Singh
authors: G A
authors: GA
authors: Piazza
authors: C M
authors: CM
authors: Contreras
authors: J
authors: J
authors: Panyam
authors: A P
authors: AP
authors: Singh
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001713:Biphenyl Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D017705:Lignans / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D031566:Magnolia; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D028321:Plant Preparations / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D000498:Allyl Compounds; D010636:Phenols
chemical_list: D000893:Anti-Inflammatory Agents; D000972:Antineoplastic Agents, Phytogenic; D001713:Biphenyl Compounds; D066246:ErbB Receptors; D017705:Lignans; D016328:NF-kappa B; D028321:Plant Preparations; D050796:STAT3 Transcription Factor; D058570:TOR Serine-Threonine Kinases; C494086:STAT3 protein, human; C005499:honokiol; D000498:Allyl Compounds; D010636:Phenols; C546842:MTOR protein, human; C512478:EGFR protein, human